Determine the necessary mass, volume, or concentration for preparing a solution.
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
SKU | Size | Availability | Price | Qty |
---|---|---|---|---|
Z126002-10mg | 10mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $355.90 | |
Z126002-50mg | 50mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $1,602.90 | |
Z126002-100mg | 100mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $2,883.90 |
Synonyms | HY-70073 | AKOS016005046 | NCGC00378753-01 | DTXSID90196547 | Zaurategrast | CT7758 | CT-7758 | ZAURATEGRAST [WHO-DD] | (2S)-2-((2-Bromo-3-oxospiro(3.5)non-1-en-1-yl)amino)-3-(4-((2,7-naphthyridin-1-yl)amino)phenyl)propanoic acid | CS-0322 | UNII-06A0IC74 |
---|---|
Specifications & Purity | Moligand™, ≥99% |
Biochemical and Physiological Mechanisms | Zaurategrast(CDP-323) is an integrin inhibitor. |
Storage Temp | Store at -20°C |
Shipped In | Ice chest + Ice pads |
Grade | Moligand™ |
Action Type | INHIBITOR |
Mechanism of action | Inhibitor of integrin α4β1;Inhibitor of integrin α4β7;Inhibitor of integrin; alpha 4 subunit (antigen CD49D; alpha 4 subunit of VLA-4 receptor) |
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
IUPAC Name | (2S)-2-[(2-bromo-3-oxospiro[3.5]non-1-en-1-yl)amino]-3-[4-(2,7-naphthyridin-1-ylamino)phenyl]propanoic acid |
---|---|
INCHI | InChI=1S/C26H25BrN4O3/c27-21-22(26(23(21)32)10-2-1-3-11-26)31-20(25(33)34)14-16-4-6-18(7-5-16)30-24-19-15-28-12-8-17(19)9-13-29-24/h4-9,12-13,15,20,31H,1-3,10-11,14H2,(H,29,30)(H,33,34)/t20-/m0/s1 |
InChi Key | KYHVWHYLKOHLKA-FQEVSTJZSA-N |
Canonical SMILES | C1CCC2(CC1)C(=C(C2=O)Br)NC(CC3=CC=C(C=C3)NC4=NC=CC5=C4C=NC=C5)C(=O)O |
Isomeric SMILES | C1CCC2(CC1)C(=C(C2=O)Br)N[C@@H](CC3=CC=C(C=C3)NC4=NC=CC5=C4C=NC=C5)C(=O)O |
PubChem CID | 10186367 |
Molecular Weight | 521.42 |
PubChem CID | 10186367 |
---|---|
CAS Registry No. | 455264-31-0 |
ChEMBL Ligand | CHEMBL4303708 |
Enter Lot Number to search for COA:
Solubility | DMSO |
---|
Pictogram(s) | GHS08 |
---|---|
Signal | Warning |
Hazard Statements | H361:Suspected of damaging fertility or the unborn child |
Precautionary Statements | P280:Wear protective gloves/protective clothing/eye protection/face protection. P405:Store locked up. P501:Dispose of contents/container to ... P203:Obtain, read and follow all safety instructions before use. P318:if exposed or concerned, get medical advice. |
1. Davenport RJ, Munday JR. (2007) Alpha4-integrin antagonism--an effective approach for the treatment of inflammatory diseases?. Drug Discov Today, 12 (13-14): (569-76). [PMID:17631252] [10.1021/op500134e] |
2. Chanteux H, Staelens L, Mancel V, Gerin B, Boucaut D, Prakash C, Nicolas JM. (2015) Cross-Species Differences in the Preclinical Pharmacokinetics of CT7758, an α4β1/α4β7 Integrin Antagonist.. Drug Metab Dispos, 43 (9): (1381-91). [PMID:26153275] [10.1021/op500134e] |
3. Li H, Huang SY, Shi FH, Gu ZC, Zhang SG, Wei JF. (2018) α4β7 integrin inhibitors: a patent review.. Expert Opin Ther Pat, 28 (12): (903-917). [PMID:30444683] [10.1021/op500134e] |